
Angarus Therapeutics
Angarus: Innovating precise immuno-oncology therapies for a targeted and powerful cancer attack.

Angarus: Innovating precise immuno-oncology therapies for a targeted and powerful cancer attack.
Founded with the mission to revolutionize cancer treatment, Angarus Therapeutics focuses on developing precision immuno-oncology therapies. Their core vision is to defeat cancer from within by creating therapeutics that target both immune-activating and immunosuppressive pathways within the tumor microenvironment. Utilizing predictive biomarkers, Angarus aims to deliver more powerful, precise, and coordinated attacks against cancer, enhancing the immune system's ability to combat tumors effectively.
Angarus Therapeutics has attracted notable investors and affiliations within the biotech industry, contributing to its rapid advancements and recognition. The company has achieved significant milestones in preclinical trials, demonstrating the potential of their innovative approach. By pioneering a new class of precision therapeutics, Angarus is making a substantial impact on the field of cancer treatment, offering hope for more effective and personalized cancer therapies.
Companies similar to Angarus Therapeutics include PineTree Therapeutics, Aulos Bioscience, Immune-Onc Therapeutics and Larkspur Biosciences.
Angarus Therapeutics was founded in 2018.
Angarus Therapeutics' headquarters is located in Portola Valley, CA, US.
Angarus Therapeutics' most recent funding round was for $11.3M (USD) in December 2020.
As of Dec 29, 2020, Angarus Therapeutics has disclosed funding of $11.3M (USD). Undisclosed round amounts are excluded.
Angarus Therapeutics has 75 employees as of Feb 5, 2024.

Larkspur Biosciences
larkspur.bio